Greenwich LifeSciences, Inc.
GLSI
$9.46
-$0.40-4.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.06M | 1.64M | 1.54M | 1.56M | 1.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.01M | 10.76M | 10.54M | 9.62M | 9.33M |
| Operating Income | -16.01M | -10.76M | -10.54M | -9.62M | -9.33M |
| Income Before Tax | -15.79M | -10.50M | -10.22M | -9.24M | -8.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.79 | -10.50 | -10.22 | -9.24 | -8.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.79M | -10.50M | -10.22M | -9.24M | -8.89M |
| EBIT | -16.01M | -10.76M | -10.54M | -9.62M | -9.33M |
| EBITDA | -16.01M | -10.76M | -10.53M | -9.62M | -9.32M |
| EPS Basic | -1.21 | -0.81 | -0.79 | -0.72 | -0.69 |
| Normalized Basic EPS | -0.76 | -0.51 | -0.50 | -0.45 | -0.43 |
| EPS Diluted | -1.21 | -0.81 | -0.79 | -0.72 | -0.69 |
| Normalized Diluted EPS | -0.76 | -0.51 | -0.50 | -0.45 | -0.43 |
| Average Basic Shares Outstanding | 52.06M | 51.76M | 51.46M | 51.40M | 51.39M |
| Average Diluted Shares Outstanding | 52.06M | 51.76M | 51.46M | 51.40M | 51.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |